Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.69 |
| ▸ | RAC1 | P63000 | 5/20 | 0.61 |
| ▸ | CDC42 | P60953 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29546268 | 0.99 | RAD52 (0.67) | RAD52RAC1CDC42MAPTMCL1 | |
| Hydrochloric Acid SCHEMBL424548 | 0.99 | RAD52 (0.67) | RAD52RAC1CDC42MAPTMCL1 | |
| Hydrochloric Acid SCHEMBL436618 | 0.97 | RAD52 (0.66) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL13839324 | 0.91 | RAD52 (0.81) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL17029135 | 0.84 | RAD52 (0.71) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL9679413 | 0.84 | RAC1 (0.69) | RAD52RAC1CDC42MAPTMCL1 | |
| Hydrochloric Acid SCHEMBL8709312 | 0.83 | RAC1 (0.70) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL15413681 | 0.82 | RAC1 (0.71) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL9679427 | 0.81 | RAC1 (0.69) | RAD52RAC1CDC42MAPTMCL1 | |
| SCHEMBL15586083 | 0.81 | RAD52 (0.54) | RAD52RAC1CDC42MAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 866 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210120808-A1 | Methods and Systems for Synergistic Continuity Approaches to Treatment and Preservation of Biological Cells | MEMBRANE PROTECTIVE TECHNOLOGIES, INC. | 2021-04-29 | — | — | US | claimed |
| US-10980798-B2 | Pharmaceutical compositions of hydrophobic camptothecin derivatives | TAIWAN LIPOSOME COMPANY, LTD. (TW) | 2021-04-20 | — | — | US | claimed |
| EP-3714037-A1 | METHODS AND SYSTEMS FOR SYNERGISTIC CONTINUITY APPROACHES TO TREATMENT AND PRESERVATION OF BIOLOGICAL CELLS | Membrane Protective Technologies, Inc. (US) | 2020-09-30 | — | — | EP | claimed |
| US-20190321356-A1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | TAIWAN LIPOSOME CO., LTD. (TW) | 2019-10-24 | — | — | US | claimed |
| EP-3500271-A1 | GENOME EDITING ENHANCERS | Bluebird Bio, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| US-20190169597-A1 | GENOME EDITING ENHANCERS | BLUEBIRD BIO, INC. (US) | 2019-06-06 | — | — | US | claimed |
| WO-2019104184-A1 | METHODS AND SYSTEMS FOR SYNERGISTIC CONTINUITY APPROACHES TO TREATMENT AND PRESERVATION OF BIOLOGICAL CELLS | MEMBRANE PROTECTIVE TECHNOLOGIES, INC. (US) | 2019-05-31 | — | — | WO | claimed |
| CN-109715171-A | Genome editor's enhancer | 蓝鸟生物公司 | 2019-05-03 | — | — | CN | claimed |
| WO-2018035423-A1 | GENOME EDITING ENHANCERS | BLUEBIRD BIO, INC. (US) | 2018-02-22 | — | — | WO | claimed |
| EP-1261337-B1 | TOPOISOMERASE INHIBITORS FOR TREATMENT OF SURGICAL ADHESIONS | UNIV BRITISH COLUMBIA (CA) | 2008-09-10 | — | — | EP | claimed |
| EP-1676577-A1 | Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide | CELGENE CORPORATION (US) | 2006-07-05 | — | — | EP | claimed |
| EP-1307197-B1 | COMPOSITIONS FOR THE TREATMENT OF CANCER COMPRISING A TOPOISOMERASE INHIBITOR AND THALIDOMIDE | CELGENE CORP (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | PFIZER INC. | 2005-08-25 | — | — | US | claimed |
| EP-1307197-A2 | COMPOSITIONS FOR THE TREATMENT OF CANCER COMPRISING A TOPOISOMERASE INHIBITOR AND THALIDOMIDE | CELGENE CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020035090-A1 | Compositions and methods for the treatment of cancer | CELGENE CORPORATION | 2002-03-21 | — | — | US | claimed |
| WO-2001087307-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELGENE CORP. (US) | 2001-11-22 | — | — | WO | claimed |
| EP-3244930-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2026-05-06 | — | — | EP | disclosed |
| US-RE50880-E1 | Anti-human OX40L antibodies and methods of treatment | KYMAB LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-0108147-A1 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-05-16 | — | — | EP | disclosed |
| WO-1983003970-A1 | COMPOUNDS, COMPOSITIONS AND METHOD OF TREATMENT FOR IMPROVING CIRCULATORY PERFORMANCE | MAROKO PETER R | 1983-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321356-A1 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES | TOP1, TOP2A, TOP2B | RAD52 1930/4885RAC1 3831/4885CDC42 454/4885 |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | TOP2A, TOP2B, TOP1 | RAD52 52/4885RAC1 4122/4885CDC42 2639/4885 |
| US-10980798-B2 | Pharmaceutical compositions of hydrophobic camptothecin derivatives | TOP1, TOP2A, TOP2B | RAD52 1930/4885RAC1 3831/4885CDC42 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.